Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.78 |
| ▸ | FLT4 | P35916 | 2/20 | 0.78 |
| ▸ | FLT1 | P17948 | 1/20 | 0.78 |
| ▸ | MET | P08581 | 4/20 | 0.44 |
| ▸ | AURKA | O14965 | 3/20 | 0.44 |
| ▸ | TEK | Q02763 | 3/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.44 |
| ▸ | CSF1R | P07333 | 2/20 | 0.43 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fruquintinib SCHEMBL947183 | 0.88 | KDR (1.00) | KDRFLT4FLT1METAURKA | |
| Fruquintinib SCHEMBL29516397 | 0.88 | KDR (1.00) | KDRFLT4FLT1METAURKA | |
| Fruquintinib SCHEMBL29366206 | 0.88 | KDR (1.00) | KDRFLT4FLT1METAURKA | |
| SCHEMBL12909830 | 0.87 | KDR (0.87) | KDRFLT4FLT1METAURKA | |
| SCHEMBL945594 | 0.83 | KDR (0.83) | KDRFLT4FLT1METAURKA | |
| SCHEMBL30753458 | 0.81 | KDR (0.79) | KDRFLT4FLT1 | |
| SCHEMBL30753470 | 0.81 | KDR (0.79) | KDRFLT4FLT1 | |
| SCHEMBL30753475 | 0.81 | KDR (0.79) | KDRFLT4FLT1 | |
| SCHEMBL11931690 | 0.81 | KDR (0.81) | KDRFLT4FLT1METAURKA | |
| SCHEMBL11931698 | 0.80 | KDR (0.83) | KDRFLT4FLT1METAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021143671-A1 | PHARMACEUTICAL COMPOSITION OF ANTI-PD-1 ANTIBODY AND QUINAZOLINE DERIVATIVE, USES OF COMPOSITION, AND METHOD FOR USING SAME | 信达生物制药(苏州)有限公司 | 2021-07-22 | — | — | WO | disclosed |